FORT LAUDERDALE, FL / ACCESSWIRE / October 25, 2024 / EndoUVtech, a leading innovator in stroke treatment technology, today announced the successful filings of its second patent in its worldwide patent protection strategy. This comprehensive strategy ensures global market coverage for EndoUVtechs revolutionary UV Laser system.
The newly filed patents extend intellectual property protection for EndoUVtechs technology to key markets such as Australia, EU, China, Israel, Canada, Japan, Brazil, Thailand, India, New Zealand, Qatar, Indonesia, Costa Rica, Colombia, Vietnam, and many more.
“We are thrilled to announce this significant milestone in securing worldwide patent protection for our groundbreaking stroke treatment technology,” said Henry “Chip” Van Vurst, CEO of EndoUVtech. “The EndoUVtech laser system has the potential to revolutionize vascular neurosurgical intervention and dramatically improve stroke patient outcomes. This global reach will allow us to bring this innovative technology to a wider audience and make a positive impact on the lives of patients all around the world.”
EndoUVtech’s unique UV intervention works by safely triggering a photochemical reaction that produces nitric oxide within the occluded artery, causing immediate dilation. This reduces friction and prevents further damage to the artery when the clot is removed mechanically. Additionally, the system improves reperfusion of the small distal vessels, significantly reducing long-term stroke side effects, such as behavioral abnormalities. “There’s nothing else available that can do this,” Van Vurst added.
About EndoUVtech
EndoUVtech is a medical technology company focused on developing innovative, minimally invasive solutions to improve patient outcomes in neurosurgery. The company’s flagship product, the EndoUVtech laser system, is a revolutionary technology designed to provide neurosurgeons with the ability to dramatically enhance stroke patient outcomes. EndoUVtech is committed to advancing the field of neurosurgery and improving the lives of patients worldwide.
Contact:
Riley Gibson, Project Manager, riley@endouvtech.com
Chip Van Vurst, CEO, chip@endouvtech.com
www.endouvtech.com
SOURCE: EndoUVtech
View the original press release on accesswire.com
GUILDFORD, SURREY / ACCESS Newswire / January 12, 2026 / CelLBxHealth plc (AIM:CLBX), a leader…
Ad hoc announcement pursuant to Art. 53 LR 2025 marks a key execution year in…
Preliminary, directional read of planned 88-investor sample indicates heightened proof thresholds (unit economics, reimbursement, outcomes)…
• Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at…
LegitScript-certified telehealth platform publishes consumer analysis as searches for GLP-1 weight loss information reach record…
Independent investigation examines castor oil, tea tree oil, and salicylic acid formulation claims in the…